Skip to main content
Erschienen in: Journal of Neuro-Oncology 2/2010

01.01.2010 | Clinical Study - Patient Study

Comparing neuropsychological tasks to optimize brief cognitive batteries for brain tumor clinical trials

verfasst von: Sarah K. Lageman, Jane H. Cerhan, Dona E. C. Locke, S. Keith Anderson, Wenting Wu, Paul D. Brown

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Neuropsychological tests are increasingly being used as outcome measures in clinical trials of brain tumor therapies. This study informs development of brief neurocognitive batteries for clinical trials by identifying cognitive tasks that detect effects on a group level in a mixed brain tumor population. This is a retrospective study of brain tumor patients who completed a standardized battery sampling multiple cognitive domains using twelve subtests with widely-used task formats (the Repeatable Battery for the Assessment of Neuropsychological Status). Sixty-eight patients with brain tumors were studied (60% high-grade glioma). Forty patients (58.8%) were impaired (>2 standard deviations below published means) on at least one subtest. A combination of four subtests (Figure Copy, Coding, List Recognition, and Story Recall) captured 90% of the impaired subgroup. These results suggest visuoconstruction, processing speed, and verbal memory measures may be the most important domains to assess when evaluating cognitive change in brain tumor clinical trials.
Literatur
1.
Zurück zum Zitat Brown PD, Buckner JC, O’Fallon JR, Iturria NL, O’Neill BP, Brown CA, Scheithauer BW, Dinapoli RP, Arusell RM, Curran WJ, Abrams R, Shaw EG (2004) Importance of baseline mini-mental state examination as a prognostic factor for patients with low-grade glioma. Int J Radiat Oncol Biol Phys 59:117–125PubMed Brown PD, Buckner JC, O’Fallon JR, Iturria NL, O’Neill BP, Brown CA, Scheithauer BW, Dinapoli RP, Arusell RM, Curran WJ, Abrams R, Shaw EG (2004) Importance of baseline mini-mental state examination as a prognostic factor for patients with low-grade glioma. Int J Radiat Oncol Biol Phys 59:117–125PubMed
2.
Zurück zum Zitat Taphoorn MJ, Klein M (2004) Cognitive deficits in adult patients with brain tumours. Lancet Neurol 3:159–168CrossRefPubMed Taphoorn MJ, Klein M (2004) Cognitive deficits in adult patients with brain tumours. Lancet Neurol 3:159–168CrossRefPubMed
3.
Zurück zum Zitat Meyers CA, Hess KR, Yung WK, Levin VA (2000) Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol 18:646–650PubMed Meyers CA, Hess KR, Yung WK, Levin VA (2000) Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol 18:646–650PubMed
4.
Zurück zum Zitat Meyers CA, Smith JA, Bezjak A, Mehta MP, Liebmann J, Illidge T, Kunkler I, Caudrelier JM, Eisenberg PD, Meerwaldt J, Siemers R, Carrie C, Gaspar LE, Curran W, Phan SC, Miller RA, Renschler MF (2004) Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 22:157–165CrossRefPubMed Meyers CA, Smith JA, Bezjak A, Mehta MP, Liebmann J, Illidge T, Kunkler I, Caudrelier JM, Eisenberg PD, Meerwaldt J, Siemers R, Carrie C, Gaspar LE, Curran W, Phan SC, Miller RA, Renschler MF (2004) Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 22:157–165CrossRefPubMed
5.
Zurück zum Zitat Meyers CA, Hess KR (2003) Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression. Neuro Oncol 5:89–95CrossRefPubMed Meyers CA, Hess KR (2003) Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression. Neuro Oncol 5:89–95CrossRefPubMed
6.
Zurück zum Zitat Meyers CA, Brown PD (2006) Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors. J Clin Oncol 24:1305–1309CrossRefPubMed Meyers CA, Brown PD (2006) Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors. J Clin Oncol 24:1305–1309CrossRefPubMed
7.
Zurück zum Zitat Lehmann JF, DeLisa JA, Warren CG, deLateur BJ, Bryant PL, Nicholson CG (1978) Cancer rehabilitation: assessment of need, development, and evaluation of a model of care. Arch Phys Med Rehabil 59:410–419PubMed Lehmann JF, DeLisa JA, Warren CG, deLateur BJ, Bryant PL, Nicholson CG (1978) Cancer rehabilitation: assessment of need, development, and evaluation of a model of care. Arch Phys Med Rehabil 59:410–419PubMed
8.
Zurück zum Zitat Meyers CA, Boake C (1993) Neurobehavioral disorders in brain tumor patients: rehabilitation strategies. Cancer Bull 45:362–364 Meyers CA, Boake C (1993) Neurobehavioral disorders in brain tumor patients: rehabilitation strategies. Cancer Bull 45:362–364
9.
Zurück zum Zitat Taphoorn MJ, Heimans JJ, Snoek FJ, Lindeboom J, Oosterink B, Wolbers JG, Karim AB (1992) Assessment of quality of life in patients treated for low-grade glioma: a preliminary report. J Neurol Neurosurg Psychiatry 55:372–376CrossRefPubMed Taphoorn MJ, Heimans JJ, Snoek FJ, Lindeboom J, Oosterink B, Wolbers JG, Karim AB (1992) Assessment of quality of life in patients treated for low-grade glioma: a preliminary report. J Neurol Neurosurg Psychiatry 55:372–376CrossRefPubMed
10.
Zurück zum Zitat Archibald YM, Lunn D, Ruttan LA, Macdonald DR, Del Maestro RF, Barr HW, Pexman JH, Fisher BJ, Gaspar LE, Cairncross JG (1994) Cognitive functioning in long-term survivors of high-grade glioma. J Neurosurg 80:247–253CrossRefPubMed Archibald YM, Lunn D, Ruttan LA, Macdonald DR, Del Maestro RF, Barr HW, Pexman JH, Fisher BJ, Gaspar LE, Cairncross JG (1994) Cognitive functioning in long-term survivors of high-grade glioma. J Neurosurg 80:247–253CrossRefPubMed
11.
Zurück zum Zitat Hahn CA, Dunn RH, Logue PE, King JH, Edwards CL, Halperin EC (2003) Prospective study of neuropsychologic testing and quality-of-life assessment of adults with primary malignant brain tumors. Int J Radiat Oncol Biol Phys 55:992–999PubMed Hahn CA, Dunn RH, Logue PE, King JH, Edwards CL, Halperin EC (2003) Prospective study of neuropsychologic testing and quality-of-life assessment of adults with primary malignant brain tumors. Int J Radiat Oncol Biol Phys 55:992–999PubMed
12.
Zurück zum Zitat Maire JP, Coudin B, Guerin J, Caudry M (1987) Neuropsychologic impairment in adults with brain tumors. Am J Clin Oncol 10:156–162CrossRefPubMed Maire JP, Coudin B, Guerin J, Caudry M (1987) Neuropsychologic impairment in adults with brain tumors. Am J Clin Oncol 10:156–162CrossRefPubMed
13.
Zurück zum Zitat Herman MA, Tremont-Lukats I, Meyers CA, Trask DD, Froseth C, Renschler MF, Mehta MP (2003) Neurocognitive and functional assessment of patients with brain metastases: a pilot study. Am J Clin Oncol 26:273–279CrossRefPubMed Herman MA, Tremont-Lukats I, Meyers CA, Trask DD, Froseth C, Renschler MF, Mehta MP (2003) Neurocognitive and functional assessment of patients with brain metastases: a pilot study. Am J Clin Oncol 26:273–279CrossRefPubMed
14.
Zurück zum Zitat Li J, Bentzen SM, Renschler M, Mehta MP (2007) Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. J Clin Oncol 25:1260–1266CrossRefPubMed Li J, Bentzen SM, Renschler M, Mehta MP (2007) Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. J Clin Oncol 25:1260–1266CrossRefPubMed
15.
Zurück zum Zitat Mehta MP, Shapiro WR, Glantz MJ, Patchell RA, Weitzner MA, Meyers CA, Schultz CJ, Roa WH, Leibenhaut M, Ford J, Curran W, Phan S, Smith JA, Miller RA, Renschler MF (2002) Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J Clin Oncol 20:3445–3453CrossRefPubMed Mehta MP, Shapiro WR, Glantz MJ, Patchell RA, Weitzner MA, Meyers CA, Schultz CJ, Roa WH, Leibenhaut M, Ford J, Curran W, Phan S, Smith JA, Miller RA, Renschler MF (2002) Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J Clin Oncol 20:3445–3453CrossRefPubMed
16.
Zurück zum Zitat Regine WF, Schmitt FA, Scott CB, Dearth C, Patchell RA, Nichols RC Jr, Gore EM, Franklin RLIII, Suh JH, Mehta MP (2004) Feasibility of neurocognitive outcome evaluations in patients with brain metastases in a multi-institutional cooperative group setting: results of Radiation Therapy Oncology Group trial BR-0018. Int J Radiat Oncol Biol Phys 58:1346–1352CrossRefPubMed Regine WF, Schmitt FA, Scott CB, Dearth C, Patchell RA, Nichols RC Jr, Gore EM, Franklin RLIII, Suh JH, Mehta MP (2004) Feasibility of neurocognitive outcome evaluations in patients with brain metastases in a multi-institutional cooperative group setting: results of Radiation Therapy Oncology Group trial BR-0018. Int J Radiat Oncol Biol Phys 58:1346–1352CrossRefPubMed
17.
Zurück zum Zitat van Nieuwenhuizen D, Klein M, Stalpers LJ, Leenstra S, Heimans JJ, Reijneveld JC (2007) Differential effect of surgery and radiotherapy on neurocognitive functioning and health-related quality of life in WHO grade I meningioma patients. J Neurooncol 84:271–278CrossRefPubMed van Nieuwenhuizen D, Klein M, Stalpers LJ, Leenstra S, Heimans JJ, Reijneveld JC (2007) Differential effect of surgery and radiotherapy on neurocognitive functioning and health-related quality of life in WHO grade I meningioma patients. J Neurooncol 84:271–278CrossRefPubMed
18.
Zurück zum Zitat Meyers CA, Wefel JS (2003) The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity. J Clin Oncol 21:3557–3558CrossRefPubMed Meyers CA, Wefel JS (2003) The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity. J Clin Oncol 21:3557–3558CrossRefPubMed
19.
Zurück zum Zitat Randolph C (1998) Manual—Repeatable Battery for the Assessment of Neuropsychological Status. The Psychological Corporation, San Antonio, TX Randolph C (1998) Manual—Repeatable Battery for the Assessment of Neuropsychological Status. The Psychological Corporation, San Antonio, TX
20.
Zurück zum Zitat Strauss E, Sherman EMS, Spreen O (2006) Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). In: A compendium of neuropsychological tests: administration, norms, and commentary. Oxford University Press, New York, NY, pp 237–258 Strauss E, Sherman EMS, Spreen O (2006) Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). In: A compendium of neuropsychological tests: administration, norms, and commentary. Oxford University Press, New York, NY, pp 237–258
21.
Zurück zum Zitat R Development Core Team (2008) R: A language and environment for statistical computing [Computer software]. R Foundation for Statistical Computing. Vienna, Austria. Retrieved from http://www.r-project.org R Development Core Team (2008) R: A language and environment for statistical computing [Computer software]. R Foundation for Statistical Computing. Vienna, Austria. Retrieved from http://​www.​r-project.​org
22.
Zurück zum Zitat Grant R, Slattery J, Gregor A, Whittle IR (1994) Recording neurological impairment in clinical trials of glioma. J Neurooncol 19:37–49CrossRefPubMed Grant R, Slattery J, Gregor A, Whittle IR (1994) Recording neurological impairment in clinical trials of glioma. J Neurooncol 19:37–49CrossRefPubMed
23.
Zurück zum Zitat Weitzner MA, Meyers CA (1997) Cognitive functioning and quality of life in malignant glioma patients: a review of the literature. Psychooncology 6:169–177CrossRefPubMed Weitzner MA, Meyers CA (1997) Cognitive functioning and quality of life in malignant glioma patients: a review of the literature. Psychooncology 6:169–177CrossRefPubMed
24.
Zurück zum Zitat Duff K, Leber WR, Patton DE, Schoenberg MR, Mold JW, Scott JG, Adams RL (2007) Modified scoring criteria for the RBANS figures. Appl Neuropsychol 14:73–83PubMed Duff K, Leber WR, Patton DE, Schoenberg MR, Mold JW, Scott JG, Adams RL (2007) Modified scoring criteria for the RBANS figures. Appl Neuropsychol 14:73–83PubMed
Metadaten
Titel
Comparing neuropsychological tasks to optimize brief cognitive batteries for brain tumor clinical trials
verfasst von
Sarah K. Lageman
Jane H. Cerhan
Dona E. C. Locke
S. Keith Anderson
Wenting Wu
Paul D. Brown
Publikationsdatum
01.01.2010
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 2/2010
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-009-9960-y

Weitere Artikel der Ausgabe 2/2010

Journal of Neuro-Oncology 2/2010 Zur Ausgabe

Laboratory Investigation - Human/Animal Tissue

A survey of glioblastoma genomic amplifications and deletions

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.